Graft-versus-host disease: establishing IL-33 as an important costimulatory molecule

James Ferrara, Mariano Prado-Acosta

*J Clin Invest.* 2022;132(12):e160692. [https://doi.org/10.1172/JCI160692.](https://doi.org/10.1172/JCI160692)

Commentary

Approximately half of patients with hematologic malignancy who are treated with allogeneic hematopoietic stem cell transplantation (alloHCT) experience graft-versus-host disease (GVHD), which has high mortality rates despite immunosuppressive therapy. IL-12 is known to drive donor T cells toward an inflammatory Th1 lineage in GVHD, but other mechanisms also promote pathological Th1 alloimmune responses. In this issue of the *JCI,* Dwyer et al. report on their use of transgenic mice and alloHCT models of GVHD to demonstrate that IL-33 acts directly on donor T cells to increase Tbet expression independently of IL-12. Notably, IL-33 amplified T cell receptor–signaling pathways and inhibited production of regulatory molecules. These findings firmly establish IL-33 as an important costimulatory molecule for Th1 cells during GVHD and provide a target for reducing GVHD, especially in the gastrointestinal (GI) tract, where damage drives mortality.

Find the latest version:

[https://jci.me/160692/pdf](https://jci.me/160692/pdf)
T cells attack normal tissues
Allogeneic hematopoietic cell transplantation (alloHCT) is a life-saving therapy used to cure aggressive hematologic malignancies, such as acute leukemia and relapsed lymphoma. The curative potential of HCT derives from the elimination of cancer cells by the T lymphocytes in the donor graft, a process called the graft-versus-leukemia (GVL) effect. The antigenic stimuli for the donor T cells are histocompatibility antigens present on both normal and malignant cells of the host, and as a result, the donor T cells attack normal tissues as well. Thus, the beneficial GVL effect closely associates with graft-versus-host disease (GVHD). The role of IL-33 in GVHD

GVHD has both acute and chronic manifestations and is lethal when severe; approximately half of all alloHCT recipients experience either acute or chronic GVHD despite prophylaxis with combination immunosuppressive therapy. Acute GVHD affects three target organs: the gastrointestinal (GI) tract, the liver, and the skin (1). If GVHD fails to respond to immunosuppressive therapy with high-dose systemic corticosteroids, the prognosis is poor and mortality can exceed 50%. The GI tract is often the most resistant to treatment, and thus understanding the pathobiology of GVHD in the GI tract is an intensive focus of HCT research.

The role of IL-33 in GVHD
Previous studies have shown an important role for IL-33 in the GI tract during the development of GVHD (2). Nonhematopoietic cells of the intestine are major sources of IL-33 in both clinical GVHD and experimental models, and the absence of IL-33 dramatically suppresses TNF-α in the serum and reduces GVHD severity in experimental models of alloHCT. Administration of IL-33 increases TNF-α production, increases the number of effector T cells in the lamina propria, and increases GVHD severity; administration of soluble ST2 (the IL-33 receptor) to block IL-33 binding to membrane-bound ST2 on donor T cells reduces inflammatory cytokines, attenuates GVHD damage to the GI tract, and improves overall survival. Yet IL-33 has a paradoxical role in the immunopathophysiology of various disease models where it can increase the stability and function of Tregs that act as an important break on inflammatory responses (3-5). Indeed, IL-33 increases the number of Tregs when administered to mice prior to alloHCT; these IL-33-expanded Tregs prevent the activation of macrophages and reduce the number of effector T cells that damage GVHD target tissues (6). Given these paradoxical effects of IL-33 on the severity of GVHD, it is critical to understand its molecular mechanism of action in greater detail.

IL-33 was thought to act primarily as an adjuvant to IL-12 produced by antigen-presenting cells (APCs) that drive donor T cells toward an inflammatory Th1 lineage (7). In this issue of the JCI, Dwyer et al. demonstrate that IL-33 acts directly on T cells to increase Tbet expression independently of IL-12. Notably, IL-33 amplified T cell receptor–signaling pathways and inhibited production of regulatory molecules. These findings firmly establish IL-33 as an important costimulatory molecule for Th1 cells during GVHD and provide a target for reducing GVHD, especially in the gastrointestinal (GI) tract, where damage drives mortality.

Related Article: https://doi.org/10.1172/JCI50927

Conflict of Interest: JF has received research funding from Mesoblast and receives royalties from Viracor for intellectual property: patent 16/343,382, titled “Prediction of graft versus host disease.”
Copyright: © 2022 Ferrara et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Reference information: J Clin Invest. 2022;132(12):e160692. https://doi.org/10.1172/JCI160692.
The importance of IL-33 in GVHD is underscored by the finding that the serum concentration of soluble ST2 predicts GVHD severity and subsequent mortality. ST2 was first validated as a serum biomarker that predicted steroid-resistant acute GVHD (11). Subsequent work showed that combining ST2 analysis with a second serum biomarker, regenerating islet-derived 3-an antimicrobial peptide produced by Paneth cells, predicted long-term outcomes of GVHD (12–14). Each biomarker by itself has approximately the same predictive power, but only these two synergize effectively to predict long-term outcomes, probably because they reflect activation and damage of two separate components of the GI tract, the mesenchyme and epithelium (15). Thus, the combination of the two has been described as a liquid biopsy of the GI tract that can monitor intestinal GVHD damage and guide immunosuppressive therapy (16).

Conclusions and future directions
The study by Dwyer et al. firmly establishes IL-33 as an important costimulatory molecule for Th1 cells in the GI tract during acute GVHD (8). Several questions deserve further consideration. Most importantly, how is IL-33, which is normally sequestered in the nucleus, released from cells and how can that process be inhibited to reduce GVHD? Second, what are the relative contributions of damaged GI epithelium and inflamed mesenchyme to the release of IL-33, and how do these processes relate to each other both temporally and spatially? Third, does IL-33 act as a similar costimulatory molecule for CD8+ T cells that also mediate acute GVHD? And does IL-33 play an important role in late acute GVHD by strengthening T cell receptor signaling when a small number of minor histocompatibility antigens in the host stimulate donor T cells several months following HCT? And finally, does manipulation of the IL-33/ST2 axis impair the GVL response, which determines the curative potential of alloHCT for hematologic malignancies? As future studies illuminate these issues, we may be able to devise therapeutic strategies to reduce or treat GVHD, especially in the GI tract, for which the unmet medical need is greatest and where progress is most likely to make alloHCT safer and more effective for all patients.

Acknowledgments
This work was supported by NIH PO1 CA039542.

Address correspondence to: James Ferrara, 1470 Madison Avenue, Rm. 6-110 New York, New York 10029, USA. Phone: 212.824.9365; Email: james.ferrara@mssm.edu.

1. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167-2179.

2. Reichenbach DK, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015;125(20):3183-3192.

3. Schiering C, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-568.

4. Xie D, et al. IL-33/ST2 axis protects against traumatic brain injury through enhancing the function of regulatory T cells. Front Immunol. 2022;13:860772.

5. Venkatadi R, et al. Targeting regulatory T cells for therapy of lupus nephritis. Front Pharmacol. 2021;12:806612.

6. Matta BM, et al. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016;128(5):427-439.

7. Liew FY, et al. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676-689.

8. Dwyer G. IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease. J Clin Invest. 2022;132(12):e150927.

9. Koyama M, Hill GR. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. Blood. 2019;134(24):2139-2148.

10. Koyama M, et al. MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota. Immunity. 2019;51(5):885-898.

11. Vander Lugt MT, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.

12. Hartwell MJ, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2(3):e89798.

13. Major-Monfried H, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131(25):2846-2855.

14. Srinagesh HK, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.

15. Etra AM, et al. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification [published online April 20, 2022]. Blood Adv. https://doi.org/10.1182/bloodadvances.2022007296.

16. Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv. 2018;2(22):3411-3417.